Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes.
Dyslipidaemia is a common cardiovascular risk factor in insulin resistant subjects with obesity, type 2 diabetes mellitus and the metabolic syndrome. Lipoprotein metabolism is complex and abnormal plasma concentrations result from alterations in the rates of production and/or catabolism of diverse lipoprotein particles. Understanding the dysregulation and therapeutic correction of lipoprotein transport in insulin resistant states has relied on the use of stable isotope tracers and modelling methods. The effects of lifestyle and therapeutic interventions on the kinetics of apolipoproteins B-100 and A-I containing lipoproteins are reviewed.
Watts
Gerald F
GF
Lipid Disorders Clinic and Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. gerald.watts@uwa.edu.au
Chan
Dick C
DC
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D019587:Dietary Supplements; D050171:Dyslipidemias / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D007700:Kinetics; D008074:Lipoproteins / Q000378:metabolism; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D008074:Lipoproteins